Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Revista Brasileira de Hematologia e Hemoterapia

Monika Conchon²  Carla Maria Boquimpani De Moura Freitas¹  Maria Aparecida Do Carmo Rego¹  José Wilson Ramos Braga Junior¹ 

[1] ,Hospital Santa Marcelina Hematology Service São Paulo SP ,Brazil

关键词: Leukemia;    Myelogenous;    Chronic;    BCR-ABL Positive;    Drug toxicity;    Drug interactions;    Gastrointestinal tract;    Drug resistance;    neoplasm;    Pyrimidines;    Interferonalpha;    Piperazines;    Clinical Trial;   

DOI  :  10.5581/1516-8484.20110034

来源: SciELO

【 摘 要 】

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License